

WHAT IS CLAIMED IS:

1. A method of preparing an antigen presenting cell specific to an antigen, said method comprising:
 - 5 (a) providing a human monocyte or monocyte-related cell;
 - (b) increasing the level of a 4-1BBL in said monocyte or monocyte-related cell;
 - (c) increasing the level of a B7 molecule in said monocyte or monocyte-related cell;
 - 10 (d) contacting said monocyte or monocyte-related cell with said antigen or a part thereof; and
 - (e) culturing said monocyte or monocyte-related cell for less than 1 week thereby to allow its conversion to an antigen presenting cell.
- 15 2. The method of claim 1, wherein said level of a 4-1BBL is increased by introducing into said monocyte or monocyte-related cell a nucleic acid encoding said 4-1BBL.
- 20 3. The method of claim 2, wherein said nucleic acid is introduced into said monocyte by introducing into said monocyte a vector comprising said nucleic acid.
4. The method of claim 3, wherein said vector is a viral
25 vector.
5. The method of claim 4, wherein said vector is an adenovirus.
- 30 6. The method of claim 1, wherein said level of a B7 molecule is increased by introducing into said monocyte or monocyte-related cell a nucleic acid encoding said B7 molecule.

7. The method of claim 6, wherein said nucleic acid is introduced into said monocyte by introducing into said monocyte a vector comprising said nucleic acid.

5

8. The method of claim 7, wherein said vector is a viral vector.

9. The method of claim 8, wherein said vector is an adenovirus.

10

10. The method of claim 2, wherein said level of a B7 molecule is increased by introducing into said monocyte or monocyte-related cell a nucleic acid encoding said B7 molecule.

15

11. The method of claim 10, wherein said nucleic acid encoding said 4-1BBL is introduced into said monocyte or monocyte-related cell by introducing into said monocyte or monocyte-related cell a vector comprising said nucleic acid encoding said 4-1BBL, and wherein said nucleic acid encoding said B7 molecule is introduced into said monocyte or monocyte-related cell by introducing into said monocyte or monocyte-related cell a vector comprising said nucleic acid encoding said B7 molecule.

20

25

12. The method of claim 11, wherein said vector comprising said nucleic acid encoding said 41BBL and said vector comprising said nucleic acid encoding said B7 molecule are each independently a viral vector.

30

13. The method of claim 4, wherein said viral vector is an adenovirus.

14. The method of claim 1, wherein said method further comprises contacting said T cell with a TNF ligand.
- 5 15. The method of claim 14, wherein said TNF ligand is selected from the group consisting of OX40L, LIGHT, CD70, CD30 and GITR-L.
16. The method of claim 1, wherein said culturing step (e)
10 has a duration of less than about 72 hours.
17. The method of claim 16, wherein said culturing step (e) has a duration of less than about 48 hours.
- 15 18. The method of claim 17, wherein said culturing step (e) has a duration of less than about 24 hours.
19. The method of claim 18, wherein said culturing step (e) has a duration of less than about 16 hours.
20
20. The method of claim 19, wherein said culturing step (e) has a duration of about 12 to about 16 hours.
21. The method of claim 1, wherein said antigen or part
25 thereof is selected from a virus, a protein and a polypeptide.
22. The method of claim 21, wherein said protein or polypeptide is contacted with said monocyte or monocyte-related cell by introducing into said monocyte or
30 monocyte-related cell a nucleic acid capable of encoding said protein or said polypeptide.

23. An antigen presenting cell produced by the method of claim 10, wherein said antigen presenting cell comprises:
- (a) a recombinant vector comprising said nucleic acid encoding said 41BBL; and
 - 5 (b) a recombinant vector comprising said nucleic acid encoding said B7 molecule.
24. The antigen presenting cell of claim 24, wherein the same vector comprises both said nucleic acid encoding said
- 10 41BBL and said nucleic acid encoding said B7 molecule.
25. A composition comprising the antigen presenting cell of claim 23 and a pharmaceutically acceptable carrier.
- 15 26. A vaccine comprising the antigen presenting cell of claim 23.
27. A method of activating a human T cell, said method comprising contacting said T cell with the antigen
- 20 presenting cell of claim 23.
28. The method of claim 27, wherein said contacting step is carried out *ex vivo*.
- 25 29. The method of claim 27, wherein said contacting step is carried out *in vivo* and said antigen presenting cell is administered to a subject comprising said human T cell.
- 30 30. The method of claim 27, wherein said human T cell is obtained from a subject suffering from a condition associated with immuno impairment.

31. The method of claim 30, wherein said condition is selected from the group consisting of viral disease, pathogen infection and cancer.

5 32. The method of claim 31, wherein said viral disease is selected from the group consisting of AIDS, hepatitis C, and CMV-related disease.

10 33. The method of claim 31, wherein said pathogen is selected from the group consisting of a bacteria, a fungus and a parasite.

15 34. A method of treating a subject suffering from a condition associated with immuno impairment, said method comprising administering to said subject the antigen presenting cell of claim 23.

20 35. A method of vaccinating a subject, said method comprising administering to said subject the antigen presenting cell of claim 23.

25 36. A method of treating a subject suffering from a condition associated with immuno impairment, said method comprising administering to said subject an activated T cell of claim prepared by the method of claim 27.

37. The method of claim 1, wherein said B7 molecule is selected from the group consisting of B7.1 and B7.2.